SCHEMBL2325901

SCHEMBL2325901

COP(=O)(CC(=O)c1cn(C)nc1C(F)(F)F)OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.52
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
STING1 Q86WV6 1/20 0.37
NTRK1 P04629 1/20 0.34
DGAT1 O75907 3/20 0.33
BACE1 P56817 2/20 0.33
BACE2 Q9Y5Z0 2/20 0.33
NPC1 O15118 1/20 0.33
PKM P14618 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32
APH1A Q96BI3 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2325906 0.80 GAA (0.46) GAALMNAPOLBSTING1NTRK1
SCHEMBL2328757 0.80 GAA (0.44) GAAPOLBNPC1CYP1A2CYP2C9
SCHEMBL27755461 0.78 GAA (0.49) GAALMNAPOLBSTING1NTRK1
SCHEMBL13064423 0.77 GAA (0.54) GAALMNAPOLBSTING1NTRK1
SCHEMBL6887159 0.76 GAA (0.68) GAALMNAPOLBSTING1NPC1
SCHEMBL15774096 0.76 GAA (0.52) GAALMNAPOLBSTING1NTRK1
SCHEMBL2322832 0.76 GAA (0.31) GAA
SCHEMBL1122502 0.74 GAA (0.65) GAALMNAPOLBSTING1NTRK1
SCHEMBL2322517 0.74 MET (0.41) GAAPOLBNPC1CYP1A2CYP2C9
SCHEMBL19182678 0.74 GAA (0.56) GAALMNAPOLBSTING1NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 GAA 3130/4885LMNA 2625/4885POLB 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.